Find Paper, Faster
Example:10.1021/acsami.1c06204 or Chem. Rev., 2007, 107, 2411-2502
Lessons from SGLT-2 inhibitors: rethinking endpoints for heart failure studies
Nature Medicine  (IF53.44),  Pub Date : 2021-11-11, DOI: 10.1038/s41591-021-01565-6
Sheng Fu, Sheldon E. Litwin, Ryan J. Tedford

SGLT-2 inhibitors show promise for treatment of heart failure with preserved ejection fraction, but clinical data are nuanced. Appropriate endpoint selection will be key to deciphering their benefits.